Long-term Clinical and Biological Evaluation of Patients With Severe Forms of Pemphigus Treated by Rituximab (Suiviritux)

University Hospital, Rouen

Status and phase: Completed; Phase 3

Conditions: Pemphigus

Treatments: Drug: Rituximab

Study type: Interventional

Funder types: Other

Identifiers

NCT01299857

2009/141/HP

Details and patient eligibility

About

The purpose of this study is to study the midterm clinical evaluation, biological parameters and immune reconstitution after Rituximab treatment for Pemphigus.

Enrollment: 22 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• age>18
• consentment
• patient treated with Rituximab and included in clinical trial n°2002/020/HP - NCT00213512 "Treatment of Patients Presenting Pemphigus With Anti CD20 (Mabthera)".

Exclusion criteria

• age < 18
• no consentment